This session will discuss how cocaine-use disorder and obesity share common neurobiological underpinnings. Two novel drug combinations are indicated for obesity: bupropion-naltrexone and topiramate-phentermine. The initial efficacy and safety of a range of doses of these drug combinations for cocaine-use disorder were determined in separate studies. The bupropion-naltrexone combinations significantly reduced cocaine self-administration but not beyond the effects of the constituent drugs alone. The topiramate-phentermine combinations reduced cocaine self-administration beyond the effects of the constituent drugs alone. The presenter will discuss the efficacy of such combinations for cocaine-use disorder.

Objectives:
- Recognize the neurobiological overlap of cocaine-use disorder and obesity.
- Recognize the need for translational research in stimulant-use disorders.
- Recite the drug combinations that reduced cocaine self-administration.